Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (30)
Merle Claßen & André Hoerning. (2023) Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies. Children 10:4, pages 634.
Crossref
Crossref
Letícia Rodrigues de Souza, Daniela Oliveira Magro, Fábio Vieira Teixeira, Rogério Serafim Parra, Eron Fábio Miranda, Omar Féres, Rogério Saad-Hossne, Giedre Soares Prates Herrerias, Renato Mitsunori Nisihara, Claudio Saddy Rodrigues Coy, Ligia Yukie Sassaki & Paulo Gustavo Kotze. (2023) Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study. Pharmaceutics 15:2, pages 586.
Crossref
Crossref
T.B. van der Houwen, B. Humer, T.O. Missotten, A.A.H.J. Thiadens, P.M. van Hagen & J.A.M. van Laar. (2023) Long-term data on efficacy and safety of adalimumab in Behçet's disease. Clinical Immunology 247, pages 109242.
Crossref
Crossref
Yushan Pan, Waseem Ahmed, Prerna Mahtani, Rochelle Wong, Randy Longman, Dana Jeremy Lukin, Ellen J Scherl & Robert Battat. (2022) Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn’s Disease. Inflammatory Bowel Diseases 28:12, pages 1865-1871.
Crossref
Crossref
Andrea Casasola-LaMacchia, Robert Joseph Seward, Sophie Tourdot, Matthew Willetts, Gary Kruppa, Michael J. Agostino, Gabrielle Bergeron, Nathalie Ahyi-Amendah, Andrew Ciarla, Zhaojiang Lu, Hai-Young Kim, Timothy P. Hickling & Hendrik Neubert. (2022) HLAII peptide presentation of infliximab increases when complexed with TNF. Frontiers in Immunology 13.
Crossref
Crossref
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim & Chang Hwan Choi. (2022) Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study. Intestinal Research 20:3, pages 350-360.
Crossref
Crossref
Nilesh Lodhia & Shanti Rao. (2022) Updates in therapeutic drug monitoring in inflammatory bowel disease. World Journal of Gastroenterology 28:21, pages 2282-2290.
Crossref
Crossref
Giorgia Bodini, Maria Giulia Demarzo, Afscin Djahandideh, Sebastiano Ziola, Paolo Risso, Lorenzo Bertani, Isabella Baldissarro, Tommaso Testa, Santino Marchi, Edoardo Savarino & Edoardo Giovanni Giannini. (2021) Therapeutic drug monitoring in Crohn’s disease patients treated with anti-TNF: a comparison of two techniques. European Journal of Gastroenterology & Hepatology 34:4, pages 382-388.
Crossref
Crossref
Joel Tan Joel Tan, Teresa Neeman & Kavitha Subramaniam Kavitha Subramaniam. (2022) The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease. Gastroenterology & Hepatology: Open Access 13:2, pages 53-58.
Crossref
Crossref
Hendrik Rusche, Edoardo Marrani, Feliciana Real-Fernandez, Roberta Ponti, Francesco Terzani, Ilaria Maccora, Olivier Monasson, Maria Vincenza Mastrolia, Elisa Peroni, Ilaria Pagnini, Rolando Cimaz, Anna Maria Papini, Gabriele Simonini & Paolo Rovero. (2021) A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. Scientific Reports 11:1.
Crossref
Crossref
Niels Vande Casteele, Brian G Feagan, Douglas C Wolf, Anca Pop, Mohamed Yassine, Sara N Horst, Timothy E Ritter & William J Sandborn. (2021) Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflammatory Bowel Diseases 27:8, pages 1346-1355.
Crossref
Crossref
Guanglin Cui, Qingbo Fan, Zhenfeng Li, Rasmus Goll & Jon Florholmen. (2021) Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. eBioMedicine 66, pages 103329.
Crossref
Crossref
Giuseppe Privitera, Daniela Pugliese, Gian Ludovico Rapaccini, Antonio Gasbarrini, Alessandro Armuzzi & Luisa Guidi. (2021) Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. Journal of Clinical Medicine 10:4, pages 853.
Crossref
Crossref
Antonello Di Paolo & Giacomo Luci. (2021) Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Frontiers in Pharmacology 11.
Crossref
Crossref
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher, Ulrika L Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Víctor Manuel Navas-López, Salvatore Oliva, Lissy de Ridder, Richard K Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine & Frank M Ruemmele. (2021) The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis 15:2, pages 171-194.
Crossref
Crossref
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M Irving, Jørgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber & Silvio Danese. (2021) Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflammatory Bowel Diseases 27:1, pages 106-122.
Crossref
Crossref
Melissa Joyce SamSusan Jane Connor, Watson Wa-Sang Ng & Catherine Mei-Ling Toong. (2020) Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies. Therapeutic Drug Monitoring 42:6, pages 821-828.
Crossref
Crossref
Marjorie Argollo, Paulo Gustavo Kotze, Pradeep Kakkadasam & Geert D’Haens. (2020) Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. Nature Reviews Gastroenterology & Hepatology 17:11, pages 702-710.
Crossref
Crossref
Nina Levhar, Bella Ungar, Uri Kopylov, Ella Fudim, Miri Yavzori, Orit Picard, Ninette Amariglio, Yehuda Chowers, Yonat Shemer-Avni, Ren Mao, Min-hu Chen, Ziyin Ye, Rami Eliakim & Shomron Ben-Horin. (2020) Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 26:9, pages 1330-1339.
Crossref
Crossref
Saiqa Muneer, Godwin A. Ayoko, Nazrul Islam & Emad L. Izake. (2020) Utilizing the thiol chemistry of biomolecules for the rapid determination of anti-TNF-α drug in blood. Talanta 208, pages 120411.
Crossref
Crossref
Amy J. Guido, Wallace Crandall, Emily Homan, Jennifer Dotson, Ross M. Maltz, Amy Donegan, Barbara Drobnic, Melanie Oates & Brendan Boyle. (2020) Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 70:1, pages 48-54.
Crossref
Crossref
Giorgia Bodini, Claudia Zanella, Mattia Crespi, Sara Lo Pumo, Maria Giulia Demarzo, Edoardo Savarino, Vincenzo Savarino & Edoardo G. Giannini. (2019) A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. Nutrition 67-68, pages 110542.
Crossref
Crossref
Niels Vande Casteele, Filip Baert, Sumin Bian, Erwin Dreesen, Griet Compernolle, Gert Van Assche, Marc Ferrante, Severine Vermeire & Ann Gils. (2019) Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study. Journal of Crohn's and Colitis 13:10, pages 1248-1256.
Crossref
Crossref
Thomas X. Lu & Russell D. Cohen. (2019) Maneuvering Clinical Pathways for Crohn’s Disease. Current Gastroenterology Reports 21:5.
Crossref
Crossref
Hannah Morgan, Su-Yi Tseng, Yann Gallais, Margret Leineweber, Pascale Buchmann, Sabrina Riccardi, Myriam Nabhan, Jeannette Lo, Zaahira Gani, Natacha Szely, Cornelia S. Zhu, Ming Yang, Andrea Kiessling, Hans-Werner Vohr, Marc Pallardy, Fred Aswad & Isabelle Turbica. (2019) Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates. Frontiers in Immunology 10.
Crossref
Crossref
Bram Verstockt, Gitte Moors, Sumin Bian, Thomas Van Stappen, Gert Van Assche, Séverine Vermeire, Ann Gils & Marc Ferrante. (2018) Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Alimentary Pharmacology & Therapeutics 48:7, pages 731-739.
Crossref
Crossref
Luc J. J. Derijks, Dennis R. Wong, Daniel W. Hommes & Adriaan A. van Bodegraven. (2018) Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics 57:9, pages 1075-1106.
Crossref
Crossref
Davide Giuseppe Ribaldone, Tilde Manetta, Giulio Mengozzi, Giorgio Maria Saracco, Rinaldo Pellicano & Marco Astegiano. (2018) Adalimumab trough levels predict Crohn’s disease clinical course. Digestive and Liver Disease 50:2, pages 204-206.
Crossref
Crossref
Xavier Roblin, Gilles Boschetti, Gérard Duru, Nicolas Williet, Emilie Deltedesco, Jean M. Phelip, Laurent Peyrin-Biroulet, Stéphane Nancey, Bernard Flourié & Stéphane Paul. (2017) Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 23:11, pages 2048-2053.
Crossref
Crossref
Mariam Aguas Peris, Virginia Bosó, Belén Navarro, Maria R. Marqués-Miñana, Guillermo Bastida, Belén Beltrán, Marisa Iborra, Esteban Sáez-González, Emilio Monte-Boquet, Jose L. Poveda-Andrés & Pilar Nos. (2017) Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflammatory Bowel Diseases 23:8, pages 1454-1460.
Crossref
Crossref